Israel Bendit

List of Publications by Year
in descending order

90 papers	1,768 citations	394421 19 h-index	302126 39 g-index
93 all docs	93 docs citations	93 times ranked	2477 citing authors

#	Article	IF	Citations
1	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013, 121, 4439-4442.	1.4	546
2	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021, 35, 440-453.	7.2	159
3	Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. Journal of Hematology and Oncology, 2009, 2, 42.	17.0	69
4	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Phâ€‰+â€‰ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia, 2019, 33, 1910-1922.	7.2	54
5	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia, 2016, 30, 1844-1852.	7.2	51
6	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood, 2020, 135, 870-875.	1.4	48
7	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	3.2	46
8	Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. Advances in Hematology, 2010, 2010, 1-4.	1.0	42
9	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia, 2017, 31, 2529-2531.	7.2	41
10	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematology,the, 2016, 3, e581-e591.	4.6	34
11	Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. International Journal of Hematology, 2008, 88, 243-245.	1.6	28
12	Molecular and immunohistochemical analysis of P53 in phaeochromocytoma. British Journal of Cancer, 1995, 72, 1211-1213.	6.4	27
13	Current patient management of chronic myeloid leukemia in Latin America. Cancer, 2010, 116, 4991-5000.	4.1	23
14	Pretherapeutic Expression of the <i>hOCT1</i> Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 228-234.	1.4	23
15	N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma. Cancer, 1990, 65, 2572-2575.	4.1	22
16	Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Research, 2004, 7, R28-32.	5.0	22
17	Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 103-8.	0.7	22
18	Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities. Clinical Microbiology and Infection, 2013, 19, E31-E43.	6.0	21

#	Article	IF	Citations
19	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. Blood, 2019, 134, 951-959.	1.4	21
20	Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil â€“ Early Deaths Are StillÂaÂProblem. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e116-e122.	0.4	20
21	Growth Hormone and Insulin-like Growth Factor I Axis and Growth of Children With Different Sickle Cell Anemia Haplotypes. The American Journal of Pediatric Hematology/oncology, 2001, 23, 357-363.	1.3	19
22	CK-19 Expression by RT-PCR in the Peripheral Blood of Breast Cancer Patients Correlates with Response to Chemotherapy. Breast Cancer Research and Treatment, 2001, 66, 249-254.	2.5	19
23	Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 124, 105-109.	1.4	16
24	Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Design, Development and Therapy, 2013, 7, 699.	4.3	16
25	Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. Practical Laboratory Medicine, 2016, 4, 30-37.	1.3	16
26	Dynamic expression of desmin, Î±-SMA and TGF-Î²1 during hepatic fibrogenesis induced by selective bile duct ligation in young rats. Brazilian Journal of Medical and Biological Research, 2014, 47, 850-857.	1.5	15
27	BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Investigation, 2015, 33, 451-458.	1.3	15
28	Concomitant p53 mutation and MYCN amplification in neuroblastoma. , 1997, 29, 206-207.		14
29	Peripheral Blood c-erbB-2 Expression by Reverse Transcriptaseâ€"Polymerase Chain Reaction in Breast Cancer Patients Receiving Chemotherapy. Clinical Breast Cancer, 2002, 3, 201-205.	2.4	14
30	Ethnic Differences in Cerebral Venous Thrombosis. Cerebrovascular Diseases, 2005, 19, 147-151.	1.7	14
31	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 211-215.	0.7	14
32	Effects of selective bile duct ligation on liver parenchyma in young animals: histologic and molecular evaluations. Journal of Pediatric Surgery, 2012, 47, 513-522.	1.6	14
33	Mdm2 mRNA expression in salivary gland tumour cell lines. Journal of Oral Pathology and Medicine, 2004, 33, 96-101.	2.7	12
34	Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. Cancer Genetics and Cytogenetics, 1995, 84, 105-112.	1.0	11
35	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Advances, 2020, 4, 2339-2350.	5.2	11
36	Deletion of the factor IX gene as a result of translocation t(X;1) in a girl affected by haemophilia B. British Journal of Haematology, 2001, 113, 616-620.	2.5	10

#	Article	IF	Citations
37	Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. Leukemia Research, 2001, 25, 711-717.	0.8	10
38	Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. International Journal of Hematology, 2009, 89, 123-125.	1.6	10
39	Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leukemia and Lymphoma, 2015, 56, 1787-1792.	1.3	10
40	BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. Medical Hypotheses, 2016, 97, 22-25.	1.5	10
41	Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. Journal of Thrombosis and Thrombolysis, 2020, 49, 667-672.	2.1	9
42	Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leukemia Research, 1998, 22, 1003-1007.	0.8	8
43	The performance of semi-quantitative differential PCR is similar to that of real-time PCR for the detection of the MYCN gene in neuroblastomas. Brazilian Journal of Medical and Biological Research, 2009, 42, 791-795.	1.5	8
44	Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. Pediatric Blood and Cancer, 2011, 56, 749-756.	1.5	8
45	Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. Acta Haematologica, 2012, 128, 223-232.	1.4	8
46	Expression Profile Analysis of Genes Related to Resistance/Sensibility to Prednisolone, Daunorubicin, L-Asparaginase and Vincristine in Childhood Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 3463-3463.	1.4	8
47	Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S6413.	1.3	7
48	Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 367-382.	0.7	7
49	N-myc Oncogene Expression in Porcine Renal Development and Oncogenesis. Pediatric Research, 1991, 29, 268-271.	2.3	6
50	Cytokeratin 19 Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients. Tumori, 2005, 91, 248-252.	1.1	6
51	Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Hematology, 2010, 10, 7.	2.6	6
52	Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. Hematology, Transfusion and Cell Therapy, 2020, 42, 261-268.	0.2	6
53	COVID-19 in chronic myeloid leukemia patients in Latin America. Leukemia and Lymphoma, 2021, 62, 3212-3218.	1.3	6
54	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. Leukemia and Lymphoma, 2021, 62, 147-157.	1.3	6

#	Article	IF	Citations
55	MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial. Leukemia Research, 2021, 101, 106516.	0.8	5
56	Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation. Hematology, 2022, 27, 396-403.	1.5	5
57	Simultaneous Occurrence of Biphenotypic T Cell/Myeloid Lesions Involving t(12;13)(p13;q14) in a Pediatric Patient. Acta Haematologica, 2012, 127, 165-169.	1.4	4
58	Non-neoplastic bulky mediastinal mass presentation in an adolescent patient: a case report. Journal of Medical Case Reports, 2013, 7, 233.	0.8	4
59	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. Blood, 2018, 132, 46-46.	1.4	4
60	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. Blood, 2011, 118, 2535-2535.	1.4	4
61	Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. Clinics, 2020, 75, e1566.	1.5	4
62	Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprungâ€™s disease. Pediatric Surgery International, 2008, 24, 1017-1021.	1.4	3
63	AvaliaÃ§Ã£o do percentual de compatibilidade HLA entre membros da mesma famÃlia para pacientes Ã espera de transplante de medula Ã³ssea em Santa Catarina, Brasil. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	3
64	Early Detection of t(8;21) Chromosomal Translocations during Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S6446.	1.3	3
65	Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation. Bone Marrow Transplantation, 2010, 45, 1125-1126.	2.4	3
66	Guideline on myeloproliferative neoplasms: AssociacÃ£o Brasileira de Hematologia, Hemoterapia e Terapia Cellular. Hematology, Transfusion and Cell Therapy, 2019, 41, 1-73.	0.2	3
67	Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management. Hematology, Transfusion and Cell Therapy, 2021, 43, 50-57.	0.2	3
68	Molecular phenotype of a pediatric small round cell tumor. Cancer, 1990, 66, 1534-1538.	4.1	2
69	Complete response to imatinib mesylate treatment in a 12â€monthâ€old patient with chronic myeloid leukemia. Pediatric Blood and Cancer, 2008, 50, 1078-1078.	1.5	2
70	The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation, 2009, 2009, 1-4.	0.5	2
71	Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma. Hematology, Transfusion and Cell Therapy, 2019, 41, 50-56.	0.2	2
72	MEG3 and MEG8 aberrant methylation in an infant with neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28328.	1.5	2

#	Article	IF	Citations
73	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 2021, 11, 1675.	3.3	2
74	Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study. Blood, 2019, 134, 5844-5844.	1.4	2
75	Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia. American Journal of Hematology, 2022, 97, E72.	4.1	2
76	Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 56-59.	1.4	1
77	Primary Myelofibrosis Brazilian Patient Journey: From Initial Symptoms To Treatment. Blood, 2013, 122, 5255-5255.	1.4	1
78	Effect of continued imatinib (IM) in pts with detectable BCR-ABL after â‰¥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. Journal of Clinical Oncology, 2014, 32, 7025-7025.	1.6	1
79	Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment. Blood, 2018, 132, 4760-4760.	1.4	1
80	Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL. Blood, 2021, 138, 4482-4482.	1.4	1
81	Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S375.	0.4	0
82	Scientific comment on: â€œAnalysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazonâ€• Who likes to take medicine forever?. Hematology, Transfusion and Cell Therapy, 2019, 41, 103.	0.2	0
83	Challenges in Chronic Myeloid Leukemia Management in South America. Current Hematologic Malignancy Reports, 2021, 16, 440-447.	2.3	0
84	MonitoraÃ§Ã£o molecular da Leucemia MielÃ³ide CrÃ´nica na era do imatinibe. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	0
85	Efeitos adversos e resposta citogenÃ©tica em pacientes com leucemia mieloide crÃ´nica tratados com imatinibe. Revista Brasileira De Hematologia E Hemoterapia, 2010, 32, 98-98.	0.7	0
86	Clonal Dasatinib Large Granular Expansion Is Associated with Suboptimal and Optimal Leukemia Net Response Criteria in Chronic Myelogenous Leukemia. Blood, 2011, 118, 1696-1696.	1.4	0
87	WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil. Blood, 2018, 132, 5288-5288.	1.4	0
88	Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country. Blood, 2020, 136, 22-23.	1.4	0
89	COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience. Blood, 2020, 136, 48-49.	1.4	0
90	Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice. Hematology, Transfusion and Cell Therapy, 2022, , .	0.2	0